Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9742121 | 0.68 | ALDH1A1 (0.34) | ALDH1A1CYP3A4 | |
| SCHEMBL4276905 | 0.68 | CYP1A2 (0.46) | GAATSHRCYP1A2 | |
| SCHEMBL207242 | 0.67 | ALDH1A1 (0.56) | GRIN1ALDH1A1GRIN2DGRIN3BGRIN2A | |
| SCHEMBL1040998 | 0.65 | ALDH1A1 (0.56) | GRIN1ALDH1A1HSD17B10KDM4EHTT | |
| SCHEMBL9740520 | 0.65 | CHUK (0.39) | GRIN1ALDH1A1GRIN2DGRIN3BGRIN2A | |
| SCHEMBL1022450 | 0.64 | RHEB (0.58) | GRIN1ALDH1A1HTTAHR | |
| SCHEMBL29531208 | 0.64 | RHEB (0.58) | GRIN1ALDH1A1HTTAHR | |
| SCHEMBL2715277 | 0.64 | ALDH1A1 (0.39) | GRIN1ALDH1A1HSD17B10GRIN2DGRIN3B | |
| SCHEMBL669692 | 0.62 | GRIN1 (0.52) | GRIN1ALDH1A1HSD17B10GRIN2DGRIN3B | |
| SCHEMBL14487466 | 0.62 | METAP2 (0.56) | GRIN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1351688-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2006-01-04 | — | — | EP | claimed |
| US-20040053963-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | claimed |
| US-20040039017-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | claimed |
| EP-1351687-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-01-21 | — | — | EP | claimed |
| EP-1351687-A2 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-15 | — | — | EP | claimed |
| EP-1351688-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2003-10-15 | — | — | EP | claimed |
| WO-2002047456-A2 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-06-20 | — | — | WO | claimed |
| WO-2002047687-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-06-20 | — | — | WO | claimed |
| EP-2588219-B1 | FILTER PLATE ARTICLE HAVING A WATER-ABSORBENT FILTER ASSEMBLY | NEOGEN FOOD SAFETY US HOLDCO CORP (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-111050765-B | Spiro compounds and methods of making and using the same | H.隆德贝克有限公司 | 2024-01-02 | — | — | CN | disclosed |
| CN-111050765-A | Spiro compounds and methods of making and using the same | 隆德贝克拉荷亚研究中心有限公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20130184258-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| EP-2588219-A2 | FILTER PLATE ARTICLE HAVING A WATER-ABSORBENT FILTER ASSEMBLY | 3M Innovative Properties Company (US) | 2013-05-08 | — | — | EP | disclosed |
| US-8309543-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-13 | — | — | US | disclosed |
| US-20040039017-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2004-02-26 | — | — | US | disclosed |
| EP-1351687-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-01-21 | — | — | EP | disclosed |
| EP-1351687-A2 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1351688-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002047456-A2 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-06-20 | — | — | WO | disclosed |
| WO-2002047687-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184258-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | GRIN1 177/4885ALDH1A1 2811/4885HSD17B10 2209/4885 |
| US-20040039017-A1 | Urotensin-II receptor antagonists | UTS2R, NTSR2, PLAUR | GRIN1 2702/4885ALDH1A1 4300/4885HSD17B10 3329/4885 |
| US-20040053963-A1 | Urotensin-II receptor antagonists | UTS2R, NTSR2, TMPRSS2 | GRIN1 3268/4885ALDH1A1 4513/4885HSD17B10 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.